August 5, 2022
Institute for Protein Design
COVID-19 vaccine with IPD nanoparticles wins full approval abroad
A vaccine for COVID-19 developed at the University of Washington School of Medicine has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older. The vaccine, now known as SKYCovione, was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria.
SK bioscience, the company leading the SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute COVID-19 vaccines around the world. In addition, the South Korean government has agreed to purchase 10 million doses for domestic use.
How do we win the fight against NTDs? Sustain. Collaborate.
In recognition of World NTD Day, we spoke to Joy Shu'aibu of Sighstavers about the road to elimination for Trachoma and other NTDs devastating communities worldwide.
How do we fix the broken US cash bail system? It starts with those most impacted.
The cash bail system in the United States is broken, the Bail Project is changing that.
Put some Audacity into your giving season!
Give boldly by supporting the work of Audacious grantees making a big impact.